Correspondence 0001193125-23-172519 from eFFECTOR Therapeutics, Inc. (EFTR, EFTRW) (CIK 0001828522)
eFFECTOR Therapeutics, Inc. (EFTR, EFTRW) (CIK 0001828522)
Date: June 22, 2023 · CIK: 0001828522 · Accession: 0001193125-23-172519
AI Filing Summary & Sentiment
File numbers found in text: 333-272738
Letter
eFFECTOR Therapeutics, Inc.
142 North Cedros Avenue, Suite B
Solana Beach, CA 92075
June 22, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: eFFECTOR Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-272738
To the addressees set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of eFFECTOR Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 26, 2023, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962, or in his absence, Anthony Gostanian of Latham & Watkins LLP at (858) 523-3969. Thank you for your assistance and cooperation in this matter.
Very truly yours,
eFFECTOR THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, CA 92075 June 22, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: eFFECTOR Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-272738 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of eFFECTOR Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 26, 2023, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962, or in his absence, Anthony Gostanian of Latham & Watkins LLP at (858) 523-3969. Thank you for your assistance and cooperation in this matter. Very truly yours, eFFECTOR THERAPEUTICS, INC. By: /s/ Michael Byrnes Michael Byrnes Chief Financial Officer cc: Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP Anthony Gostanian, Latham & Watkins LLP